Dysthyroid optic neuropathy (DON) is a severe visual loss condition in thyroid eye disease (TED). This study aimed to identify factors affecting moderate-to-severe TED or DON in Thai populations.
Methods
We retrospectively reviewed the records of 230 TED patients at Rajavithi Hospital between January 1, 2017, and October 31, 2022.
Results
Mild, moderate-to-severe TED, and DON were found in 60.43%, 22.61%, and 16.96% of participants, respectively. Female predominance was noted in all groups. The proportion of older age, hyperthyroidism, current smokers, and type 2 diabetes mellitus (T2DM) participants were significantly higher in the DON group. Multivariable logistic-regression analysis revealed that hyperthyroidism and current smoking significantly increased the risk of developing moderate-to-severe TED (OR = 3.001, p = 0.010, and OR = 4.153, p = 0.015, respectively). Exophthalmos was the strongest predictor (OR = 6.834, p < 0.001). Regarding DON risk factors, older age (≥55 years) had OR = 3.206 (p = 0.003), hyperthyroidism had OR = 3.228 (p = 0.005), and being a current smoker had OR = 3.781 (p = 0.011). T2DM posed the greatest risk of DON development (OR = 4.111, p = 0.004).
Conclusions
Hyperthyroidism and current smoking are significant risk factors for moderate-to-severe TED and DON. TED patients with diabetes mellitus or older age should be closely monitored and informed about their risk of developing DON.
BartleyGBGormanCA. Diagnostic criteria for Graves’ ophthalmopathy. Am J Ophthalmol1995; 119: 792–795.
2.
BartalenaLPiantanidaEGalloD, et al.Natural history, risk factors, and prevention of Graves’ orbitopathy. Front Endocrinol (Lausanne)2020; 11: 615993.
3.
BartalenaLKahalyGJBaldeschiL, et al.The 2021 European group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol2021; 185: G43–g67.
4.
DayanCMDayanMR. Dysthyroid optic neuropathy: a clinical diagnosis or a definable entity?Br J Ophthalmol2007; 91: 409–410.
LeeJHLeeSYYoonJS. Risk factors associated with the severity of thyroid-associated orbitopathy in Korean patients. Korean J Ophthalmol2010; 24: 267–273.
7.
PrummelMFWiersingaWMMouritsMP, et al.Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med1990; 150: 1098–1101.
8.
MuralidharADasSTipleS. Clinical profile of thyroid eye disease and factors predictive of disease severity. Indian J Ophthalmol2020; 68: 1629–1634. doi:https://doi.org/10.4103/ijo.IJO_104_20
9.
KhongJJFinchSDe SilvaC, et al.Risk factors for Graves’ orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) study. J Clin Endocrinol Metab2016; 101: 2711–2720.
10.
StarksVSReinshagenKLLeeNG,et al.Visual field and orbital computed tomography correlation in dysthyroid optic neuropathy due to thyroid eye disease. Orbit2020; 39: 77–83.
11.
BartalenaLMarcocciCBogazziF, et al.Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med1998; 338: 73–78.
12.
Le MoliRVellaVTuminoD, et al.Inflammasome activation as a link between obesity and thyroid disorders: implications for an integrated clinical management. Front Endocrinol (Lausanne)2022; 13: 959276.
13.
SabiniEMazziBProfiloMA, et al.High Serum cholesterol is a novel risk factor for Graves’ orbitopathy: results of a cross-sectional study. Thyroid2018; 28: 386–394.
14.
LanzollaGSabiniEProfiloMA, et al.Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study. J Endocrinol Invest2018; 41: 1417–1423.
15.
SteinJDChildersDGuptaS, et al.Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol2015; 133: 290–296.
16.
YeXZHuangSSLiuJ, et al.High serum cholesterol: a novel risk factor for thyroid associated ophthalmopathy?Zhonghua Nei Ke Za Zhi2019; 58: 823–825.
17.
LuCLaiCLYangCM, et al.The Relationship between obesity-related factors and Graves’ orbitopathy: A pilot study. Medicina (Kaunas)2022; 58: 1748.
18.
RathSPattnaikMTripathyD, et al.Sight-Threatening thyroid eye disease: role of diabetes mellitus and interaction with other risk factors. Ophthalmic Plast Reconstr Surg2021; 37: 352–360.
19.
MouritsMPKoornneefLWiersingaWM, et al.Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol1989; 73: 639–644.
20.
BahnRSGormanCA. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am1987; 16: 391–407.
21.
KemchoknateePTangonDSrisombutT. A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy. BMC Ophthalmol2023; 23: 32.
BirchallDGoodallKLNobleJL,et al.Graves ophthalmopathy: intracranial fat prolapse on CT images as an indicator of optic nerve compression. Radiology1996; 200: 123–127.
24.
KemchoknateePChenkhumwongseADheeradilokT,et al.Diagnostic ability of barrett's Index and presence of intracranial fat prolapse in dysthyroid optic neuropathy. Clin Ophthalmol2022; 16: 2569–2578. doi:https://doi.org/10.2147/OPTH.S364987
25.
PrummelMFWiersingaWM. Smoking and risk of Graves’ disease. Jama1993; 269: 479–482.
26.
BartalenaL. Prevention of Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab2012; 26: 371–379.
27.
PfeilschifterJZieglerR. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf)1996; 45: 477–481.
28.
WiersingaWM. Smoking and thyroid. Clin Endocrinol (Oxf)2013; 79: 145–151.
29.
PlanckTShahidaBParikhH, et al.Smoking induces overexpression of immediate early genes in active Graves’ ophthalmopathy. Thyroid2014; 24: 1524–1532.
30.
PerrosPCrombieALMatthewsJN,et al.Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf)1993; 38: 367–372.
31.
KalmannRMouritsMP. Diabetes mellitus: a risk factor in patients with Graves’ orbitopathy. Br J Ophthalmol1999; 83: 463–465.
32.
Le MoliRMusciaVTumminiaA, et al.Type 2 diabetic patients with Graves’ disease have more frequent and severe Graves’ orbitopathy. Nutr Metab Cardiovasc Dis2015; 25: 452–457.
33.
RamamurthyLBRangarajanVSriraoN, et al.Severity of thyroid eye disease and type-2 diabetes mellitus: is there a correlation?Indian J Ophthalmol2020; 68: 1127–1131.
34.
EcksteinAKLöschCGlowackaD, et al.Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol2009; 93: 1052–1056.
35.
KimJMLaBreeLLevinL,et al.The relation of Graves’ ophthalmopathy to circulating thyroid hormone status. Br J Ophthalmol2004; 88: 72–74.
36.
TallstedtLLundellGBlomgrenH,et al.Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment?Eur J Endocrinol1994; 130: 494–497.
37.
NabiTRafiqN. Factors associated with severity of orbitopathy in patients with Graves’ disease. Taiwan J Ophthalmol2020; 10: 197–202.
38.
WiersingaWMBartalenaL. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid2002; 12: 855–860.
39.
TandaMLPiantanidaELiparuloL, et al.Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab2013; 98: 1443–1449.
40.
WiersingaWŽarkovićMBartalenaL, et al.Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism. Eur J Endocrinol2018; 178: 635–643.
41.
LatAMJauculanMCSanchezCA, et al.Risk factors associated with the activity and severity of Graves’ ophthalmopathy among patients at the university of the Philippines Manila-philippine general hospital. J ASEAN Fed Endocr Soc2017; 32: 151–157.
42.
WooKIKimYDLeeSY. Prevalence and risk factors for thyroid eye disease among Korean dysthyroid patients. Korean J Ophthalmol2013; 27: 397–404.
43.
McKeagDLaneCLazarusJH, et al.Clinical features of dysthyroid optic neuropathy: a European group on Graves’ Orbitopathy (EUGOGO) survey. Br J Ophthalmol2007; 91: 455–458.
44.
MoonSJLeeWJRohTS,et al.Sex-related and racial variations in orbital floor anatomy. Arch Craniofac Surg2020; 21: 219–224.
45.
KumaranAChanAYongK,et al.Ethnic variation in deep lateral orbital anatomy and its implications on decompression surgery. Orbit2019; 38: 95–102.
46.
MoldogazievaNTMokhosoevIMMel'nikovaTI, et al.Oxidative stress and advanced lipoxidation and glycation End products (ALEs and AGEs) in aging and age-related diseases. Oxid Med Cell Longev2019; 2019: 3085756. doi:https://doi.org/10.1155/2019/3085756
